Libra Review | Choose Better

You can view the original post here WASHINGTON — The one People nonetheless not eligible for coronavirus vaccines — infants, toddlers and preschoolers — seem on the verge of lastly getting cleared to obtain them after an advisory panel to the Meals and Drug Administration voted unanimously on Wednesday to suggest the Pfizer and Moderna vaccines for the group. The F.D.A. seems poised to authorize Moderna’s vaccine for kids youthful than 6 and Pfizer’s for these youthful than 5 as quickly as Friday. States have already ordered tens of millions of doses, and White Home officers have mentioned pictures may roll out as early as subsequent week. The committee’s 21-0 votes got here after a daylong overview of scientific trial knowledge and signaled the top of a course of that concerned months of false begins and dashed hopes for a vaccine to cowl the youngest People. Aside from the roughly 20 million kids beneath 5, everybody has had entry to coronavirus pictures for a lot of months ...

Marc Leighton, VP of Product at Florence Healthcare Prior to COVID, major technological transformation initiatives were already underway at many clinical trial sites, sponsors, and contract research organizations (CROs.) But the move to decentralized trials accelerated dramatically in 2020 and 2021–and it’s not slowing down.  Survey data from WCG Avoca shows that research sites and sponsors expect 89% of clinical trials to qualify as a hybrid, with a mix of decentralized technology and in-person visits.  But what will these decentralized clinical trials (DCTs) look like? I’d like to share some bold predictions for DCTs in 2022 (and beyond!):  Sites and sponsors shouldn’t be locked into a zero-sum game against one another. In 2022, they’ll be unified by complementary technology and the common purpose of getting cures to market.  By the end of the year, I expect the majority of sites will have an electronic Investigator Site File (eISF) and electronic informed consent (eConsent)....

  Pfizer exited neuroscience drug research years ago, but the company still found a way to add a new neuro drug to its portfolio. An FDA-approved migraine drug from partner Biohaven Pharmaceuticals now has marketing authorizations in Europe, enabling the pharmaceutical giant to start capturing a share of the fast-growing product. The two companies announced Wednesday that the European Commission has approved Biohaven drug rimegepant for both migraine prevention and the treatment of acute migraine pain. The European decisions match the approved indications for the drug in the U.S., where it is marketed under the name Nurtec. In Europe, the drug will be called Vydura. The approvals in Europe are also a win for Pfizer. Last November, the pharma giant inked a deal for the right to commercialize rimegepant globally, with the exception of the U.S. where Biohaven retains rights. Pfizer paid $500 million up front, a combination cash and stock. It’s also on the hook to pay New Hav...